Abstracts tagged "biomarkers and lupus nephritis"

Abstract Number: 669 • 2017 ACR/ARHP Annual Meeting
Unbiased Screening of Urinary Protein Biomarkers for Glomerular Filtration Rate Normalization
Sanam Soomro¹, Samantha Stanley², Ramesh Saxena³, Michelle Petri⁴ and Chandra Mohan¹, ¹Biomedical Engineering, University of Houston, Houston, TX, ²Biomedical Engineering Department, University of Houston, Houston, TX, ³Internal Medicine/Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: To account for glomerular filtration rate, urinary creatinine is routinely used for the normalization of urine biomarkers related to disease. Because of the small…
Abstract Number: 1379 • 2016 ACR/ARHP Annual Meeting
Evaluation of S100 Proteins As Potential Biomarkers of Global and Renal-Specific Disease Activity in Childhood-Onset Systemic Lupus Erythematosus
Jessica Turnier¹, Ndate Fall², Sherry Thornton², Alexei Grom^2,3 and Hermine I. Brunner^4,5, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³PRCSG, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, PRCSG, Cincinnati, OH, ⁵Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a heterogeneous disease with differing levels of disease activity and organ-specific disease manifestations in each individual. In particular,…
Abstract Number: 2063 • 2016 ACR/ARHP Annual Meeting
Identification of Microrna Predictive of Outcome in Lupus Nephritis
Mohammad Hadavand¹, Nada Binmadi², Hua Zhou³, Mayank Tandon⁴, Sarfaraz Hasni⁵ and Illias Alevizos⁶, ¹National Institute of Dental and Craniofacial Research, Bethesda, MD, ²Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, Bethesda, MD, ³Molecular Physiology and Therapeutics Branch,, National Institute of Dental and Craniofacial Research, Bethesda, MD, ⁴Sjogren's Clinic, NIDCR/NIH, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD
Background/Purpose: High dose corticosteroids such as cyclophosphamide are commonly used to treat lupus nephritis (LN). Although effective in preventing end stage renal disease (ESRD)…
Abstract Number: 2817 • 2016 ACR/ARHP Annual Meeting
Identification of Subsets of Systemic Lupus Erythematosus Patients By Principal Component Analysis and Urine Biomarkers
José A. Gómez-Puerta¹, Blanca Ortiz², Tomás Urrego¹, Adriana L Vanegas³, Carlos Horacio Muñoz⁴, Mauricio Restrepo³, Wilmer Rojas-Zuleta³, Sofia Arteaga³, Luis Alonso Gonzalez⁵, Mauricio Rojas² and Gloria Vásquez^5,6, ¹Grupo de Inmunología Celular e Inmunogenética, Universidad de Antioquia, Medellín, Colombia, ²Grupo de Inmunología Celular e Inmunogenética, Facultad de Medicina, Universidad de Antioquia, medellin, Colombia, ³Rheumatology Unit, Universidad de Antioquia, Medellín, Colombia, ⁴Hospital Universitario de San Vicente Fundación, Medellín, Colombia, ⁵Rheumatology Unit, Universidad de Antioquia, Medellin, Colombia, ⁶Grupo de Inmunología Celular e Inmunogenética (GICIG), Universidad de Antioquia, Medellín, Colombia
Background/Purpose: Systemic lupus erythematosus (SLE) is clinically heterogeneous disease, with a considerably variability of disease expression among patients. There have been several attempts to classify…
Abstract Number: 720 • 2015 ACR/ARHP Annual Meeting
Biomarkers in Lupus Nephritis: The Possible Role of Serum Cystatin C, Serum β2-Microglobulin, Urinary Î±1-Microglobulin and Albuminâ�„Creatinine Ratio
Luca Petricca¹, Elisa Gremese¹, Laura Messuti¹, Franca Forni², Clara Di Mario¹, Marcin Nowik¹, Maria Rita Gigante¹, Gerardo Marino³ and Gianfranco Ferraccioli¹, ¹Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²Department of Laboratory Medicine, Catholic University of the Sacred Heart, Rome, Italy, ³Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Lupus nephritis (LN) may severely affect SLE prognosis and an effective treatment of LN requires correct diagnosis, timely intervention and early treatment of any…
Abstract Number: 1119 • 2015 ACR/ARHP Annual Meeting
High Resolution Motif Mapping of in Situ Anti-Native-Vimentin Antibodies in Lupus Tubulointerstitial Nephritis
Andrew Kinloch¹, Yuta Asano², Balazs Banfai³, Gregor Dernick³, Carole Henry Dunand⁴, Nirit Mor-Vaknin⁵, Maureen Legendre⁵, David Markovitz⁵, Thomas Schindler⁶ and Marcus R. Clark⁷, ¹University of Chicago, Chicago, IL, ²Committee of immunology, University of Chicago, Chicago, IL, ³Translational Technologies and Bioinformatics, Roche, Basel, Switzerland, ⁴Rheumatology and Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁵University of Michigan, Ann Arbor, MI, ⁶Roche Innovation Center Basel, Roche, Basel, Switzerland, ⁷Rheumatology and Knapp Center for Lupus Research, University of Chicago, Chicago, IL
Background/Purpose: Severe lupus tubulointerstitial nephritis (TIN) is prognostic of renal failure and characterized by an in situ autoantibody response. By characterizing monoclonal antibodies engineered from…
Abstract Number: 1669 • 2014 ACR/ARHP Annual Meeting
Validation of a Machine Learning Lupus Nephritis Decision Support Tool to Predict Complete Response to Therapy
Bethany Wolf¹, John Christian Spainhour¹, John Arthur², Michael Janech², Michelle Petri³, Adnan Kiani⁴ and Jim Oates^5,6, ¹Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²Medicine, Medical University of South Carolina, Charleston, SC, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴1830 E Monument St, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁶Medical Service, Ralph H. Johnson VAMC, Charleston, SC
Background/Purpose .The American College of Rheumatology treatment guidelines for lupus nephritis (LN) recommend that induction therapy be changed when response to therapy has not occurred…
Abstract Number: 1651 • 2014 ACR/ARHP Annual Meeting
Association of Glomerular Macrophage Phenotypes and Urine Soluble CD163 with Disease Activity in Human Lupus Nephritis
Naotake Tsuboi¹, Nobuhide Endo¹, Seiichi Matsuo² and Shoichi Maruyama¹, ¹Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: In addition to the effector roles of classically activated macrophages for tissue injury, recent studies have shown that alternatively activated (M2) macrophages are involved…
Abstract Number: 1304 • 2014 ACR/ARHP Annual Meeting
Development of an Index to Non-Invasively Quantify Lupus Nephritis Chronicity in Children
Khalid Abulaban¹, Michael Bennett², Marisa Klein-Gitelman³, Stacy P. Ardoin⁴, Kelly A. Rouster-Stevens⁵, Lori B. Tucker⁶, Kasha Wiley⁷, Shannen Nelson⁸, Karen Onel⁹, Nora G. Singer¹⁰, Kathleen M. O'Neil¹¹, B Anne Eberhard¹², Lawrence K. Jung¹³, Lisa F. Imundo¹⁴, Tracey Wright¹⁵, David Witte¹⁶, Jun Ying¹⁷, Prasad Devarajan² and Hermine I. Brunner¹⁸, ¹Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Anne & Robert H Lurie Childrens Hospital of Chicago, Chicago, IL, ⁴Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, ⁵Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁶Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁷Rheumatology, Cincinnati Children's Hospital Medical Center, c, OH, ⁸Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ¹⁰Medicine, Division of Rhuematology, Division of Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, ¹¹Division of Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ¹²Pediatrics/Rheumatology, Cohen Children's Medical Center, Lake Success, NY, ¹³Pediatric Rheumatology, Children's National Medical Center, Washington, DC, ¹⁴Assoociate Professor of Pediatrics in Medicine - Rheumatoology, Columbia University Medical Center, New York, NY, ¹⁵Pediatrics/Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹⁶Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ¹⁷University of Cincinnati, Cincinnati, OH, ¹⁸Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The current gold standard for assessing chronic changes in Lupus Nephritis (LN) is a kidney biopsy interpreted using the International Societies for Nephrology &…
Abstract Number: 1294 • 2014 ACR/ARHP Annual Meeting
Gender Differences in the Lupus Nephritis Biomarkers in Children
Khalid Abulaban¹, Hermine Brunner², Michael Bennett³, Shannen L. Nelson⁴, Jun Ying⁵ and Prasad Devarajan³, ¹Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵University of Cincinnati, Cincinnati, OH
Background/Purpose: Lupus nephritis (LN) is frequently associated with a poor long-term prognosis. The non-invasive traditional measures of LN (LN-TM) currently used to monitor LN have…
Abstract Number: 2797 • 2013 ACR/ARHP Annual Meeting
B-Lymphocyte Stimulator and A Proliferation Inducing Ligand In Lupus Nephritis: Low Serum Levels Of BLyS Predict Treatment Response
Ioannis Parodis¹, Agneta Zickert¹, Elisabet Svenungsson², Vivianne Malmström² and Iva Gunnarsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: B-lymphocytes have a pivotal role in the pathogenesis of Systemic Lupus Erythematosus (SLE). B-Lymphocyte Stimulator (BLyS) has an important role in the activation, differentiation…
Abstract Number: 880 • 2013 ACR/ARHP Annual Meeting
Role Of Urinary Podocyte Number and Urinary Podocalyxin Level As Biomarkers Of Glomerulonephritis In Systemic Lupus Erythematosus and ANCA-Associated Vasculitis
Hiroshi Kajiyama¹, Keiju Hiromura², Daisuke Ikuma¹, Hidekazu Ikeuchi², Hiroyuki Kurosawa³, Yoshiaki Hirayama³, Fumio Gondaira³, Masanori Hara⁴, Yoshihisa Nojima² and Toshihide Mimura⁵, ¹Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, ²Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, ³Department of reagent research and development, Denka Seiken Co. Ltd., Niigata, Japan, ⁴Department of Pediatrics, Yoshida Hospital, Niigata, Japan, ⁵Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Podocytes are glomerular visceral epithelial cells functioning as molecular sieves not to allow high molecular weight protein to leak from glomerular capillary wall. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].